© Research
Publication : Diagnostic microbiology and infectious disease

Development and evaluation of ELISA serological immunoassays for influenza and respiratory syncytial viruses.

Reference Center: Viruses of Respiratory Infections (including Influenza and SARS-CoV-2)
Member: Marie-Anne Rameix-Welti
Scientific Fields
Diseases
Organisms
Applications
Technique

Published in Diagnostic microbiology and infectious disease - 01 Jul 2025

Claudet A, Alcover N, Lebigot E, Bouhelal HS, Warnakulasuriya F, Soutiere MP, Galloux M, Eleouet JF, Rameix-Welti MA, Bizot E, Vauloup-Fellous C, Portet-Sulla V

Link to Pubmed [PMID] – 40215609

Link to DOI – 10.1016/j.diagmicrobio.2025.116835

Diagn Microbiol Infect Dis 2025 Jul; 112(3): 116835

Respiratory syncytial virus (RSV) and influenza are major causes of respiratory infections globally. Although vaccines are available, serological tools to assess population-level immunity and maternal antibody transfer remain limited. This study aimed to develop and evaluate ELISA assays for detecting anti-RSV and anti-influenza antibodies as a basis for future maternal-fetal immunity research.In this study, we designed ELISA immunoassays using various influenza and RSV antigens. Sensitivity and specificity were calculated using sera from presumed seronegative infants and seropositive adults.The influenza vaccine-based ELISA achieved 98.3 % sensitivity and 100 % specificity. The pre-fusion F protein of RSV (Arexvy®) showed 97.5 % sensitivity and 97.4 % specificity. Other antigen combinations performed less optimally.These ELISA assays are scalable tools for seroepidemiological and maternal transfer studies. Future work will include correlation with neutralizing antibodies and paired maternal-infant analyses.